Quad Capital Management Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Quad Capital Management Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$380K	Buy	100,000 +57,971	+138%	+$191K	1.21%	15
2019 Q4	$127K	Buy	+42,029	New	+$109K	1.94%	9

Other funds holding BMY.RT

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Quad Capital Management Advisors's BMY.RT Position: Q1 2020 in Review

Quad Capital Management Advisors increased its Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) stake by 138% in Q1 2020, buying an estimated $191K and bringing the position to 100,000 shares worth $380K. The position accounts for 1.21% of the portfolio, ranked #15.

Quad Capital Management Advisors first reported a position in BMY.RT in Q4 2019 and has held it in 2 quarters since. 581 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2020.

Quad Capital Management Advisors held 100,000 shares of Bristol-Myers Squibb Company Contingent Value Rights worth $380K as of Q1 2020.
Quad Capital Management Advisors bought 57,971 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2020, an estimated $191K.
Bristol-Myers Squibb Company Contingent Value Rights made up 1.21% of Quad Capital Management Advisors's portfolio in Q1 2020, its #15 holding.
Quad Capital Management Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and has held it in 2 quarters since.
581 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2020.

Based on Quad Capital Management Advisors's 13F filing for Q1 2020, filed 20 Apr 2020.